By eigindia It may be stated that the manufacture, sale and distribution of Nimesulide formulations for human use in children below 12 years of age was prohibited under Section 26A of Drugs and Cosmetics Act, 1940 vide Gazette Notification no. GSR 82(E). This decision came as a result of growing concerns about the safety of Nimesulide, particularly in pediatric patients.
Nimesulide, a non-steroidal anti-inflammatory drug (NSAID), has been widely used for the treatment of pain and fever. However, over the years, its use in children, especially under 12, raised alarms due to reports of severe adverse effects, including liver toxicity, which could lead to potentially fatal outcomes. Several countries had already restricted or banned the drug in young children due to these risks.
In India, the prohibition was enforced after reviewing available clinical evidence that suggested Nimesulide could cause severe liver damage in children. The drug was linked to several cases of acute liver failure, which, in some instances, led to the need for liver transplants. The risk was deemed to outweigh the benefits, especially considering the availability of safer alternatives for managing fever and pain in children.
This regulatory action was applauded by health experts and pediatricians, who stressed that it was crucial to safeguard the health of young patients. By limiting the use of Nimesulide, authorities aimed to prevent serious, long-term health consequences for children, while also encouraging the use of medications that have a better safety profile for this age group.
In response to the ban, many pharmaceutical companies began to comply with the new regulations, ensuring that pediatric formulations of Nimesulide were no longer available in the market. The move also sparked discussions about the need for more stringent drug safety measures and the importance of continuously evaluating the risk-benefit balance of commonly used medications.
Ultimately, this step reinforced the commitment of the Indian government to protect public health, particularly vulnerable populations like children, from the dangers of unsafe medications. It also served as a reminder that the regulation of pharmaceutical products must be an ongoing process, adapting to emerging evidence and ensuring the safety and well-being of patients.